Molecular Templates Inc (OQ:MTEM)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 9301 Amberglen Blvd Ste 100
AUSTIN TX 78729-1153
Tel: N/A
Website: mtem.com
IR: See website
<
Key People
Harold E. Selick
Chairman of the Board
Jason Kim
President, Chief Operating Officer
Eric E. Poma
Chief Executive Officer, Chief Scientific Officer, Director
Adam D. Cutler
Chief Financial Officer, Treasurer, Secretary
   
Business Overview
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company's lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.
Financial Overview
For the nine months ended 30 September 2019, Molecular Templates Inc revenues increased 87% to $16.1M. Net loss increased from $23.7M to $53.5M. Revenues reflect Research and development revenue - from increase from $3.2M to $14.5M. Higher net loss reflects Rese increase of 48% to $32.3M (expense), General and admi increase of 39% to $11.4M (expense), Change in fair value of warrant liabilit decrease of 100% to $3K (income).
Employees: 102 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $420.42M as of Sep 30, 2019
Annual revenue (TTM): $20.76M as of Sep 30, 2019
EBITDA (TTM): -$37.68M as of Sep 30, 2019
Net annual income (TTM): -$60.17M as of Sep 30, 2019
Free cash flow (TTM): -$26.51M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 43,854,510 as of Nov 20, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization